*By Christian Smith* After an overdose earlier this week, Demi Lovato's life was reportedly saved by Narcan, a nasal administrator of naloxone that counteracts the effects of opioids. When administered quicklyーthrough either nasal mist or injectionーnaloxone can temporarily halt an overdose, allowing EMTs enough time to respond. The medication is available without a prescription in 49 states, and the generic version costs about $20 per dose. But all merits aside, is the drug's accessibility enabling addicts to push their limits? Dr. Roger Crystal, the lead inventor of Narcan and CEO of Opiant Pharmaceuticals, says there's little evidence to support that concern. "Addiction like any kind of chronic disease is something you can control using better medication, but ultimately you can't cure," Crystal told Cheddar. "To think about an opioid addict behaving rationally and saying, 'well because I have access to Narcan I'll shoot more heroin, inject more heroin' there's no proof for that whatsoever." Naloxone is considered some of the best ammunition on the front lines of America's growing opioid epidemic. A reported 2 million Americans have an addition to opioidsーand the number isn't going down. U.S. Surgeon General Jerome Adams [issued an advisory](https://www.surgeongeneral.gov/priorities/opioid-overdose-prevention/naloxone-advisory.html) in April urging anyoneーand their close family and friendsーwho uses painkillers, heroin, fentanyl, or other opioids to carry naloxone in case of an emergency. Crystal isn't stopping at Narcan: he told Cheddar he's also developing a heroin vaccine, suggesting the inventor has lofty ambitions for the future of overdose prevention. Although Crystal may be aware of lingering ethical concerns, he doesn't think they dwarf his mission. After all, Lovato has him to thank. "Putting it in the hands of everyone and anyone is critical," Crystal said. For more on this story, [click here](https://cheddar.com/videos/how-one-pharmaceutical-company-is-fighting-the-opioid-epidemic).

Share:
More In Science
Finally, the Last Breaths of Theranos
John Carreyrou, the Wall Street Journal investigative reporter who first exposed the fraud at blood-testing company Theranos, said the former CEO of the once high-flying start-up had a chance to minimize the pain years ago, but instead used what money the company had to hide the truth.
San Francisco Picks Two Start-Ups for Scooter Program, Snubbing Giants Bird and Lime
In its pick of two small start-ups over Bird, Lime, Uber, and Lyft, San Francisco sent a signal that the most valuable mobility companies' "launch first, ask questions later" approach is catching up to them. Scoot Global and Skip were chosen because they said they would keep riders off the sidewalks and would provide services to low-income residents. Meanwhile, Santa Monica announced that it would open its shared mobility pilot program to e-scooters from Uber, Lyft, Bird, and Lime.
The State of Crypto After Latest SEC Rejection
Paul Johnson, partner at Harbor Peak, said regulators are nervous about being interpreted as backing crypto investing. But Bitcoin and Ethereum continue to benefit from widespread user adoption, while other platforms will likely fade away.
Load More